Embolic strokes of unknown source and cryptogenic stroke: Implications in clinical practice

Frontiers in Neurology

Volumn 7, Issue MAR, 2016, Pages

  Nouh, Amre ^a   Hussain, Mohammed ^a   Mehta, Tapan ^a   Yaghi, Shadi ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Aortic arch atherosclerosis; Cardiac monitoring; Cryptogenic stroke; Embolic stroke of undetermined source; Hypercoagulable state; Paroxysmal atrial fibrillation; Patent foramen ovale

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; HOMOCYSTEINE;

AORTA ATHEROSCLEROSIS; AORTIC ARCH ATHEROSCLEROSIS; ATRIAL FIBRILLATION; AUTOIMMUNE DISEASE; CARDIAC IMAGING; CARDIOEMBOLIC STROKE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DEEP VEIN THROMBOSIS; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; EMBOLIC STROKE OF UNDETERMINED SOURCE; EVIDENCE BASED MEDICINE; FABRY DISEASE; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; INFLAMMATION; MIGRAINE; NEOPLASM; PARADOXICAL EMBOLISM; PATENT FORAMEN OVALE; PATIENT RISK; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VASCULITIS;

EID: 84973161259     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2016.00037     Document Type: Review

References (204)

1. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke (2001) 32(11):2559-66. doi:10.1161/hs1101.098524
2. Putaala J, Metso AJ, Metso TM, Konkola N, Kraemer Y, Haapaniemi E, et al. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke the Helsinki young stroke registry. Stroke (2009) 40(4):1195-203. doi:10.1161/STROKEAHA.108.529883
3. Li L, Yiin GS, Geraghty OC, Schulz UG, Kuker W, Mehta Z, et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. The Lancet Neurology (2015) 14(9):903-13. doi:10.1016/S1474-4422(15)00132-5
4. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 (1993) 1:35-41. doi:10.1161/01.STR.24.1.35
5. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. New approach to stroke subtyping: the ASCO (phenotypic) classification of stroke. Cerebrovasc Dis (2009) 27(5):502-8. doi:10.1159/000210433
6. Ji R, Schwamm LH, Pervez MA, Singhal AB. Ischemic stroke and transient ischemic attack in young adults: risk factors, diagnostic yield, neuroimaging, and thrombolysis. JAMA Neurol (2013) 70(1):51-7. doi:10.1001/jamaneurol.2013.575
7. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O'Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol (2014) 13(4):429-38. doi:10.1016/S1474-4422(13)70310-7
8. Ntaios G, Papavasileiou V, Milionis H, Makaritsis K, Vemmou A, Koroboki E, et al. Embolic strokes of undetermined source in the Athens stroke registry: an outcome analysis. Stroke (2015) 46(8):2087-93. doi:10.1161/STROKEAHA.115.009334
9. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2011) 42:517-84. doi:10.1161/STR.0b013e3181fcb238
10. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med (2014) 370:2467-77. doi:10.1056/NEJMoa1311376
11. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med (2014) 370:2478-86. doi:10.1056/NEJMoa1313600
12. Yaghi S, Elkind MS. Cryptogenic stroke: a diagnostic challenge. Neurol Clin Pract (2014) 4:386-93. doi:10.1212/CPJ.0000000000000086
13. Favilla CG, Ingala E, Jara J, Fessler E, Cucchiara B, Messe SR, et al. Predictors of finding occult atrial fibrillation after cryptogenic stroke. Stroke (2015) 46:1210-5. doi:10.1161/STROKEAHA.114.007763
14. Bernstein RA, Di Lazzaro V, Rymer MM, Passman RS, Brachmann J, Morillo CA, et al. Infarct topography and detection of atrial fibrillation in cryptogenic stroke: results from CRYSTAL AF. Cerebrovasc Dis (2015) 40:91-6. doi:10.1159/000437018
15. Miller DJ, Khan MA, Schultz LR, Simpson JR, Katramados AM, Russman AN, et al. Outpatient cardiac telemetry detects a high rate of atrial fibrillation in cryptogenic stroke. J Neurol Sci (2013) 324:57-61. doi:10.1016/j.jns.2012.10.001
16. Gladstone DJ, Dorian P, Spring M, Panzov V, Mamdani M, Healey JS, et al. Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the embrace trial. Stroke (2015) 46:936-41. doi:10.1161/STROKEAHA.115.008714
17. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the trends study. Circ Arrhythm Electrophysiol (2009) 2:474-80. doi:10.1161/CIRCEP.109.849638
18. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation (2014) 129:2094-9. doi:10.1161/CIRCULATIONAHA.113.007825
19. Keach JW, Bradley SM, Turakhia MP, Maddox TM. Early detection of occult atrial fibrillation and stroke prevention. Heart (2015) 101:1097-102. doi:10.1136/heartjnl-2015-307588
20. Kamel H, Elkind MS, Bhave PD, Navi BB, Okin PM, Iadecola C, et al. Paroxysmal supraventricular tachycardia and the risk of ischemic stroke. Stroke (2013) 44:1550-4. doi:10.1161/STROKEAHA.113.001118
21. Yaghi S, Moon YP, Mora-McLaughlin C, Willey JZ, Cheung K, Di Tullio MR, et al. Left atrial enlargement and stroke recurrence: the Northern Manhattan Stroke Study. Stroke (2015) 46:1488-93. doi:10.1161/STROKEAHA.115.008711
22. Kamel H, O'Neal WT, Okin PM, Loehr LR, Alonso A, Soliman EZ. Electrocardiographic left atrial abnormality and stroke subtype in atherosclerosis risk in communities study. Ann Neurol (2015) 78(5):670-8. doi:10.1002/ana.24482
23. Kamel H, Soliman EZ, Heckbert SR, Kronmal RA, Longstreth WT Jr, Nazarian S, et al. P-wave morphology and the risk of incident ischemic stroke in the multi-ethnic study of atherosclerosis. Stroke (2014) 45:2786-8. doi:10.1161/STROKEAHA.114.006364
24. Sinner MF, Stepas KA, Moser CB, Krijthe BP, Aspelund T, Sotoodehnia N, et al. B-type natriuretic peptide and c-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF consortium of community-based cohort studies. Europace (2014) 16:1426-33. doi:10.1093/europace/euu175
25. Folsom AR, Nambi V, Bell EJ, Oluleye OW, Gottesman RF, Lutsey PL, et al. Troponin t, n-terminal pro-b-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study. Stroke (2013) 44:961-7. doi:10.1161/STROKEAHA.111.000173
26. Cushman M, Judd SE, Howard VJ, Kissela B, Gutierrez OM, Jenny NS, et al. N-terminal pro-b-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort. Stroke (2014) 45:1646-50. doi:10.1161/STROKEAHA.114.004712
27. Yaghi S, Boehme AK, Hazan R, Hod EA, Canaan A, Andrews HF, et al. Atrial cardiopathy and cryptogenic stroke: a cross-sectional pilot study. J Stroke Cerebrovasc Dis (2015) 25(1):110-4. doi:10.1016/j.jstrokecerebrovasdis.2015.09.001
28. Longstreth WT Jr, Kronmal RA, Thompson JL, Christenson RH, Levine SR, Gross R, et al. Amino terminal pro-b-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy. Stroke (2013) 44:714-9. doi:10.1161/STROKEAHA.112.675942
29. Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation (2005) 112:1063-72. doi:10.1161/CIRCULATIONAHA.104.524371
30. Meier B, Frank B, Wahl A, Diener HC. Secondary stroke prevention: patent foramen ovale, aortic plaque, and carotid stenosis. Eur Heart J (2012) 33(6):705-13. doi:10.1093/eurheartj/ehr443
31. Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke incidental or pathogenic? Stroke (2009) 40(7):2349-55. doi:10.1161/STROKEAHA.109.547828
32. Lethen H, Flachskampf FA, Schneider R, Sliwka U, Köhn G, Noth J, et al. Frequency of deep vein thrombosis in patients with patent foramen ovale and ischemic stroke or transient ischemic attack. Am J Cardiol (1997) 80(8):1066-9. doi:10.1016/S0002-9149(97)00604-8
33. Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Eng J Med (2007) 357(22):2262-8. doi:10.1056/NEJMoa071422
34. Wessler BS, Thaler DE, Ruthazer R, Weimar C, Di Tullio MR, Elkind MS, et al. Transesophageal echocardiography in cryptogenic stroke and patent foramen ovale analysis of putative high-risk features from the risk of paradoxical embolism database. Circ Cardiovasc Imaging (2014) 7(1):125-31. doi:10.1161/CIRCIMAGING.113.000807
35. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology (2000) 55(8):1172-9. doi:10.1212/WNL.55.8.1172
36. Messe SR, Silverman IE, Kizer JR, Homma S, Zahn C, Gronseth G, et al. Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2004) 62(7):1042-50. doi:10.1212/01.WNL.0000119173.15878.F3
37. Claver E, Larrousse E, Bernal E, López-Ayerbe J, Valle V. Giant thrombus trapped in foramen ovale with pulmonary embolus and stroke. J Am Soc Echocardiogr (2004) 17(8):916-8. doi:10.1016/j.echo.2004.04.020
38. Liberman AL, Daruwalla VJ, Collins JD, Maas MB, Botelho MPF, Ayache JB, et al. Diagnostic yield of pelvic magnetic resonance venography in patients with cryptogenic stroke and patent foramen ovale. Stroke (2014) 45(8):2324-9. doi:10.1161/STROKEAHA.114.005539
39. Osgood M, Budman E, Carandang R, Goddeau RP Jr, Henninger N. Prevalence of pelvic vein pathology in patients with cryptogenic stroke and patent foramen ovale undergoing MRV pelvis. Cerebrovasc Dis (2015) 39(3-4):216-23. doi:10.1159/000376613
40. Spritzer CE, Arata MA, Freed KS. Isolated pelvic deep venous thrombosis: relative frequency as detected with MR imaging 1. Radiology (2001) 219(2):521-5. doi:10.1148/radiology.219.2.r01ma25521
41. Cramer SC, Rordorf G, Maki JH, Kramer LA, Grotta JC, Burgin WS, et al. Increased pelvic vein thrombi in cryptogenic stroke results of the Paradoxical Emboli From Large Veins in Ischemic Stroke (PELVIS) Study. Stroke (2004) 35(1):46-50. doi:10.1161/01.STR.0000106137.42649.AB
42. McDermott S, Oliveira G, Ergül E, Brazeau N, Wicky S, Oklu R. May-Thurner syndrome: can it be diagnosed by a single MR venography study. Diagn Interv Radiol (2013) 19(1):44-8. doi:10.4261/1305-3825.DIR.5939-12.1
43. May R, Thurner J. The cause of the predominantly sinistral occurrence of thrombosis of the pelvic veins. Angiology (1957) 8(5):419-27. doi:10.1177/000331975700800505
44. Kiernan TJ, Yan BP, Cubeddu RJ, Rengifo-Moreno P, Gupta V, Inglessis I, et al. May-Thurner syndrome in patients with cryptogenic stroke and patent foramen ovale: an important clinical association. Stroke (2009) 40(4):1502-4. doi:10.1161/STROKEAHA.108.527366
45. Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology (2013) 81(7):619-25. doi:10.1212/WNL.0b013e3182a08d59
46. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 45(7):2160-236. doi:10.1161/STR.0000000000000024
47. O'Sullivan GJ, Semba CP, Bittner CA, Kee ST, Razavi MK, Sze DY, et al. Endovascular management of iliac vein compression (May-Thurner) syndrome. J Vasc Interv Radiol (2000) 11(7):823-36. doi:10.1016/S1051-0443(07)61796-5
48. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med (2012) 366(11):991-9. doi:10.1056/NEJMoa1009639
49. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med (2013) 368(12):1083-91. doi:10.1056/NEJMoa1211716
50. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med (2013) 368(12):1092-100. doi:10.1056/NEJMoa1301440
51. Wolfrum M, Froehlich GM, Knapp G, Casaubon LK, DiNicolantonio JJ, Lansky AJ, et al. Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta-analysis. Heart (2013) 100(5):389-95. doi:10.1136/heartjnl-2013-304394
52. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP, PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale patent foramen ovale in Cryptogenic Stroke Study. Circulation (2002) 105(22):2625-31. doi:10.1161/01.CIR.0000017498.88393.44
53. Kent DM, Dahabreh IJ, Ruthazer R, Furlan AJ, Weimar C, Serena J, et al. Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis. Eur Heart J (2015) 36(35):2381-9. doi:10.1093/eurheartj/ehv252
54. Patti G, Pelliccia F, Gaudio C, Greco C. Meta-analysis of net long-term benefit of different therapeutic strategies in patients with cryptogenic stroke and patent foramen ovale. Am J Cardiol (2015) 115(6):837-43. doi:10.1016/j.amjcard.2014.12.051
55. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, et al. ACC/AHA/ASE 2003 Guideline for the Clinical Application of Echocardiography (2006). Available from: http://www.ncbi.nlm.nih.gov/pubmed/12952829
56. Barkhausen J, Hunold P, Eggebrecht H, Schüler WO, Sabin GV, Erbel R, et al. Detection and characterization of intracardiac thrombi on MR imaging. AJR Am J Roentgenol (2002) 179:1539. doi:10.2214/ajr.179.6.1791539
57. Grover S, Srinivasan G, Selvanayagam JB. Myocardial viability imaging: does it still have a role in patient selection prior to coronary revascularisation? Heart, Lung Circ (2012) 21(8):468-79. doi:10.1016/j.hlc.2012.03.008
58. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson (2008) 10:35. doi:10.1186/1532-429X-10-35
59. Menghetti L, Basso C, Nava A, Angelini A, Thiene G. Spin-echo nuclear magnetic resonance for tissue characterisation in arrhythmogenic right ventricular cardiomyopathy. Heart (1996) 76:467. doi:10.1136/hrt.76.6.467
60. Beerbaum P, Körperich H, Barth P, Esdorn H, Gieseke J, Meyer H. Noninvasive quantification of left-to-right shunt in pediatric patients: phase-contrast cine magnetic resonance imaging compared with invasive oximetry. Circulation (2001) 103(20):2476.
61. Sayad DE, Willett DL, Bridges WH, Chwialkowski M, McColl R, Payne J, et al. Noninvasive quantitation of left ventricular wall thickening using cine magnetic resonance imaging with myocardial tagging. Am J Cardiol (1995) 76:985. doi:10.1016/S0002-9149(99)80280-X
62. Olin JW, Kaufman JA, Bluemke DA, Bonow RO, Gerhard MD, Jaff MR, et al. Atherosclerotic Vascular Disease Conference: writing Group IV: imaging. Circulation (2004) 109:2626. doi:10.1161/01.CIR.0000128521.02390.72
63. Summers RM, Andrasko-Bourgeois J, Feuerstein IM, Hill SC, Jones EC, Busse MK, et al. Evaluation of the aortic root by MRI: insights from patients with homozygous familial hypercholesterolemia. Circulation (1998) 98:509. doi:10.1161/01.CIR.98.6.509
64. Schiebler M, Axel L, Reichek N, Aurigemma G, Yeager B, Douglas P, et al. Correlation of cine MR imaging with two-dimensional pulsed Doppler echocardiography in valvular insufficiency. J Comput Assist Tomogr (1987) 11:627. doi:10.1097/00004728-198707000-00015
65. Pflugfelder PW, Landzberg JS, Cassidy MM, Cheitlin MD, Schiller NB, Auffermann W, et al. Comparison of cine MR imaging with Doppler echocardiography for the evaluation of aortic regurgitation. AJR Am J Roentgenol (1989) 152:729. doi:10.2214/ajr.152.4.729
66. Baher A, Mowla A, Kodali S, Polsani VR, Nabi F, Nagueh SF, et al. Cardiac MRI improves identification of etiology of acute ischemic stroke. Cerebrovasc Dis (2014) 37(4):277-84. doi:10.1159/000360073
67. Harloff A, Handke M, Reinhard M, Geibel A, Hetzel A. Therapeutic strategies after examination by transesophageal echocardiography in 503 patients with ischemic stroke. Stroke (2006) 7:859-64. doi:10.1161/01.STR.0000202592.87021.b7
68. Gupta A, Gialdini G, Lerario MP, Baradaran H, Giambrone A, Navi BB, et al. Magnetic resonance angiography detection of abnormal carotid artery plaque in patients with cryptogenic stroke. J Am Heart Assoc (2015) 4:e002012. doi:10.1161/JAHA.115.002012
69. Srichai MB, Junor C, Rodriguez LL, Stillman AE, Grimm RA, Lieber ML, et al. Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological validation. Am Heart J (2006) 152:75. doi:10.1016/j.ahj.2005.08.021
70. Weinsaft JW, Kim HW, Shah DJ, Klem I, Crowley AL, Brosnan R, et al. Detection of left ventricular thrombus by delayed-enhancement cardiovascular magnetic resonance prevalence and markers in patients with systolic dysfunction. J Am Coll Cardiol (2008) 52:148-57. doi:10.1016/j.jacc.2008.03.041
71. Freilinger TM, Schindler A, Schmidt C, Grimm J, Cyran C, Schwarz F, et al. Prevalence of nonstenosing, complicated atherosclerotic plaques in cryptogenic stroke. JACC Cardiovasc Imaging (2012) 5:397-405. doi:10.1016/j.jcmg.2012.01.012
72. Molina C, Santamarina E, Alvarez-Sabín J. Cryptogenic stroke, aortic arch atheroma and patent foramen ovale. Cerebrovasc Dis (2007) 24(Suppl 1):84-8. doi:10.1159/000107382
73. Amarenco P, Cohen A, Tzourio C, Bertrand B, Hommel M, Besson G, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med (1994) 331:1474-9. doi:10.1056/NEJM199412013312202
74. Macleod MR, Amarenco P, Davis SM, Donnan GA. Atheroma of the aortic arch: an important and poorly recognised factor in the aetiology of stroke. Lancet Neurol (2004) 3:408-14. doi:10.1016/S1474-4422(04)00806-3
75. Rundek T, Di Tullio MR, Sciacca RR, Titova IV, Mohr JP, Homma S, et al. Association between large aortic arch atheromas and high-intensity transient signals in elderly stroke patients. Stroke (1999) 33:2683-6. doi:10.1161/01.STR.30.12.2683
76. Castellanos M, Serena J, Segura T, Pérez-Ayuso MJ, Silva Y, Dávalos A. Atherosclerotic aortic arch plaques in cryptogenic stroke: a microembolic signal monitoring study. Eur Neurol (2001) 45:145-50. doi:10.1159/000052113
77. Viguier A, Pavy le Traon A, Massabuau P, Valton L, Larrue V. Asymptomatic cerebral embolic signals in patients with acute cerebral ischaemia and severe aortic arch atherosclerosis. J Neurol (2001) 248:768-71. doi:10.1007/s004150170092
78. Donohue KG, Saap L, Falanga V. Cholesterol crystal embolization: an atherosclerotic disease with frequent and varied cutaneous manifestations. J Eur Acad Dermatol Venereol (2003) 17:504. doi:10.1046/j.1468-3083.2003.00710.x
79. Amarenco P, Duyckaerts C, Tzourio C, Hénin D, Bousser MG, Hauw JJ. The prevalence of ulcerated plaques in the aortic arch in patients with stroke. N Engl J Med (1992) 326:221-5. doi:10.1056/NEJM199201233260402
80. Jones EF, Kalman JM, Calafiore P, Tonkin AM, Donnan GA. Proximal aortic atheroma. An independent risk factor for cerebral ischemia. Stroke (1995) 26:218-24.
81. Amarenco P, Cohen A, Baudrimont M, Bousser MG. Transesophageal echocardiography detection of aortic arch disease in patients with cerebral infarction. Stroke (1992) 23:1005-9. doi:10.1161/01.STR.23.7.1005
82. Stone DA, Hawke MW, LaMonte M, Kittner SJ, Acosta J, Corretti M, et al. Ulcerated atherosclerotic plaques in the thoracic aorta are associated with cryptogenic stroke: a multiplane transesophageal echocardiographic study. Am Heart J (1995) 130:105-8. doi:10.1016/0002-8703(95)90243-0
83. Di Tullio MR, Sacco RL, Gersony D, Nayak H, Weslow RG, Kargman DE, et al. Aortic atheromas and acute ischemic stroke: a transesophageal echocardiographic study in an ethnically mixed population. Neurology (1996) 46:1560-6. doi:10.1212/WNL.46.6.1560
84. Fisher CM, Gore I, Okabe N, White PD. Atherosclerosis of the carotid and vertebral arteries-Extracranial and intracranial. J Neuropathol Exp Neurol (1965) 24:455-76. doi:10.1097/00005072-196507000-00007
85. Ito A, Sugioka K, Matsumura Y, Fujita S, Iwata S, Hanatani A, et al. Rapid and accurate assessment of aortic arch atherosclerosis using simultaneous multi-plane imaging by transesophageal echocardiography. Ultrasound Med Biol (2013) 39(8):1337-42. doi:10.1016/j.ultrasmedbio.2013.03.011
86. Tunick PA, Krinsky GA, Lee VS, Kronzon I. Diagnostic imaging of thoracic aortic atherosclerosis. AJR Am J Roentgenol (2000) 174:1119. doi:10.2214/ajr.174.4.1741119
87. Tenenbaum A, Garniek A, Shemesh J, Fisman EZ, Stroh CI, Itzchak Y, et al. Dual-helical CT for detecting aortic atheromas as a source of stroke: comparison with transesophageal echocardiography. Radiology (1998) 208:153. doi:10.1148/radiology.208.1.9646807
88. Khatri IA, Mian N, Alkawi A, Janjua N, Kirmani JF, Saric M, et al. Catheter-based aortography fails to identify aortic atherosclerotic lesions detected on transesophageal echocardiography. J Neuroimaging (2005) 15:261. doi:10.1111/j.1552-6569.2005.tb00319.x
89. Di Tullio MR, Russo C, Jin Z, et al. Patent Foramen Ovale in Cryptogenic Stroke Study Investigators. Aortic arch plaques and risk of recurrent stroke and death. Circulation (2009) 119:2376-82. doi:10.1161/CIRCULATIONAHA.108.811935
90. Tunick PA, Nayar AC, Goodkin GM, Mirchandani S, Francescone S, Rosenzweig BP, et al. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol (2002) 90:1320-5. doi:10.1016/S0002-9149(02)02870-9
91. Dressler FA, Craig WR, Castello R, Labovitz AJ. Mobile aortic atheroma and systemic emboli: efficacy of anticoagulation and influence of plaque morphology on recurrent stroke. J Am Coll Cardiol (1998) 31:134-8. doi:10.1016/S0735-1097(97)00449-X
92. Ferrari E, Vidal R, Chevallier T, Baudouy M. Atherosclerosis of the thoracic aorta and aortic debris as a marker of poor prognosis: benefit of oral anticoagulants. J Am Coll Cardiol (1999) 33:1317-22. doi:10.1016/S0735-1097(99)00003-0
93. Amarenco P, Davis S, Jones EF, Cohen AA, Heiss WD, Kaste M, et al. Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques. Stroke (2014) 45(5):1248-57. doi:10.1161/STROKEAHA.113.004251
94. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 113:2363. doi:10.1161/CIRCULATIONAHA.106.174516
95. Nedeltchev K, der Maur TA, Georgiadis D, Arnold M, Caso V, Mattle HP, et al. Ischaemic stroke in young adults: predictors of outcome and recurrence. J Neurol Neurosurg Psychiatry (2005) 76(2):191-5. doi:10.1136/jnnp.2004.040543
96. Caplan LR. Dissections of brain-supplying arteries. Nat Clin Pract Neurol (2008) 4(1):34-42. doi:10.1038/ncpneuro0683
97. Gilden D, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment. Lancet Neurol (2009) 8:731-40. doi:10.1016/S1474-4422(09)70134-6
98. Askalan R, Laughlin S, Mayank S, Chan A, MacGregor D, Andrew M, et al. Chickenpox and stroke in childhood: a study of frequency and causation. Stroke (2001) 32:1257-62. doi:10.1161/01.STR.32.6.1257
99. Braun KP, Bulder MM, Chabrier S, Kirkham FJ, Uiterwaal CS, Tardieu M, et al. The course and outcome of unilateral intracranial arteriopathy in 79 children with ischaemic stroke. Brain (2009) 32:544-57. doi:10.1093/brain/awn313
100. Kang JH, Ho JD, Chen YH, Lin HC. Increased risk of stroke after a herpes zoster attack: a population-based follow-up study. Stroke (2009) 40:3443-8. doi:10.1161/STROKEAHA.109.562017
101. Lin HC, Chien CW, Ho JD. Herpes zoster ophthalmicus and the risk of stroke: a population-based follow-up study. Neurology (2010) 74:792-7. doi:10.1212/WNL.0b013e3181d31e5c
102. Nagel MA, Cohrs RJ, Mahalingam R, Wellish MC, Forghani B, Schiller A, et al. The Varicella zoster virus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology (2008) 70:853-60. doi:10.1212/01.wnl.0000304747.38502.e8
103. Bushnell CD, Goldstein LB. Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke (2000) 31(12):3067-78. doi:10.1161/01.STR.31.12.3067
104. Chan MY, Andreotti F, Becker RC. Hypercoagulable states in cardiovascular disease. Circulation (2008) 118(22):2286-97. doi:10.1161/CIRCULATIONAHA.108.778837
105. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood (2000) 95(5):1517-32.
106. Hart RG, Kanter MC. Hematologic disorders and ischemic stroke. A selective review. Stroke (1990) 21(8):1111-21. doi:10.1161/01.STR.21.8.1111
107. Bushnell C, Siddiqi Z, Morgenlander JC, Goldstein LB. Use of specialized coagulation testing in the evaluation of patients with acute ischemic stroke. Neurology (2001) 56(5):624-7. doi:10.1212/WNL.56.5.624
108. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. The Lancet (2010) 376(9751):1498-509. doi:10.1016/S0140-6736(10)60709-X
109. Marlar RA, Gausman JN. Laboratory testing issues for protein C, protein S, and antithrombin. Int J Lab Hematol (2014) 36(3):289-95. doi:10.1111/ijlh.12219
110. Piazza G. Thrombophilia testing, recurrent thrombosis, and women's health. Circulation (2014) 130(3):283-7. doi:10.1161/CIRCULATIONAHA.113.007664
111. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2011) 42(1):227-76. doi:10.1161/STR.0b013e3181f7d043
112. Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine (1985) 64(1):16-35. doi:10.1097/00005792-198501000-00002
113. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood (2007) 110(6):1723-9. doi:10.1182/blood-2006-10-053736
114. Chaturvedi P, Singh AP, Batra SK. Structure, evolution, and biology of the MUC4 mucin. FASEB J (2008) 22(4):966-81. doi:10.1096/fj.07-9673rev
115. Butenas S, Orfeo T, Mann KG. Tissue factor in coagulation Which? Where? When? Arterioscler Thromb Vasc Biol (2009) 29(12):1989-96. doi:10.1161/ATVBAHA.108.177402
116. Jander S, Sitzer M, Wendt A, Schroeter M, Buchkremer M, Siebler M, et al. Expression of tissue factor in high-grade carotid artery stenosis association with plaque destabilization. Stroke (2001) 32(4):850-4. doi:10.1161/01.STR.32.4.850
117. Bick RL. Cancer-associated thrombosis. N Engl J Med (2003) 349(2):109-10. doi:10.1056/NEJMp030086
118. Robert F. The potential benefits of low-molecular-weight heparins in cancer patients. J Hematol Oncol (2010) 3(3):1-12. doi:10.1186/1756-8722-3-3
119. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia (2002) 4(6):465. doi:10.1038/sj.neo.7900263
120. Kiechl S, Matosevic B, Willeit J. Primary central nervous system lymphoma resulting in stroke and leukoencephalopathy. In: Hayat MA, editor. Tumors of the Central Nervous System (Vol. 9), Netherlands: Springer (2012). p. 29-39.
121. Kurabayashi H, Hishinuma A, Uchida R, Makita S, Majima M. Delayed manifestation and slow progression of cerebral infarction caused by polycythemia rubra vera. Am J Med Sci (2007) 333(5):317-20. doi:10.1097/MAJ.0b013e31805370a9
122. Giray S, Sarica FB, Arlier Z, Bal N. Recurrent ischemic stroke as an initial manifestation of an concealed pancreatic adenocarcinoma: Trousseau's syndrome. Chin Med J (2011) 124(4):637-40.
123. Seok JM, Kim SG, Kim JW, Chung CS, Kim GM, Lee KH, et al. Coagulopathy and embolic signal in cancer patients with ischemic stroke. Ann Neurol (2010) 68(2):213-9. doi:10.1002/ana.22050
124. Jang H, Lee JJ, Lee MJ, Ryoo S, Yoon CH, Kim GM, et al. Comparison of enoxaparin and warfarin for secondary prevention of cancer-associated stroke. J Oncol (2015) 2015:502089. doi:10.1155/2015/502089
125. Hong CT, Tsai LK, Jeng JS. Patterns of acute cerebral infarcts in patients with active malignancy using diffusion-weighted imaging. Cerebrovasc Dis (2009) 28(4):411-6. doi:10.1159/000235629
126. Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med (2010) 123:612-6. doi:10.1016/j.amjmed.2009.12.021
127. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ (2009) 339:b3914. doi:10.1136/bmj.b3914
128. Bousser MG, Conrad J, Kittner S, de Lignières B, MacGregor EA, Massiou H, et al. Recommendations on the risk if ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society Task Force on Combined Oral Contraceptives and Hormone Replacement Therapy. Cephalalgia (2000) 20:155-6.
129. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ (2005) 330:63. doi:10.1136/bmj.38302.504063.8F
130. Kurth T, Schurks M, Logroscino G, Buring JE. Migraine frequency and risk of cardiovascular disease in women. Neurology (2009) 73:581-8. doi:10.1212/WNL.0b013e3181ab2c20
131. Schurks M, Buring JE, Kurth T. Migraine, migraine features, and cardiovascular disease. Headache (2010) 50:1031-40. doi:10.1111/j.1526-4610.2009.01609.x
132. Li L, Schulz UG, Kuker W, Rothwell PM, Oxford Vascular Study. Age-specific association of migraine with cryptogenic TIA and stroke: population-based study. Neurology (2015) 85:1444-51. doi:10.1212/WNL.0000000000002059
133. Cavestro C, Richetta L, L'Episcopo MR, Pedemonte E, Duca S, Di Pietrantonj C. Anatomical variants of the circle of Willis and brain lesions in migraineurs. Can J Neurol Sci (2011) 38:494-9. doi:10.1017/S0317167100011926
134. Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol (2013) 75:365-91. doi:10.1146/annurev-physiol-030212-183717
135. Lechat P, Mas J, Lascault G, Loron P, Theard M, Klimczac M, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med (1988) 318:1148-52. doi:10.1056/NEJM198805053181802
136. Webster M, Chancellor A, Smith H, Swift D, Sharpe D, Bass N, et al. Patent foramen ovale in young stroke patients. Lancet (1988) 2:11-2. doi:10.1016/S0140-6736(88)92944-3
137. Olesen J, Friberg L, Olsen T, Andersen A, Lassen N, Hansen P, et al. Ischaemia-induced (symptomatic) migraine attacks may be more frequent than migraine-induced ischaemic insults. Brain (1993) 116(Pt 1):187-202. doi:10.1093/brain/116.1.187
138. Dowson A, Mullen M, Peatfield R, Muir K, Khan A, Wells C, et al. Migraine Intervention With STARFlex Technology (MIST) Trial: a prospective, multicenter, double-blinded, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation (2008) 117:1397-404. doi:10.1161/CIRCULATIONAHA.107.727271
139. Tobis J. Management of patients with refractory migraine and PFO: is MIST I relevant? Catheter Cardiovasc Interv (2008) 72:60-4. doi:10.1002/ccd.21504
140. Rundek T, Elkind MS, Di Tullio MR, Carrera E, Jin Z, Sacco RL, et al. Patent foramen ovale and migraine: a cross-sectional study from the Northern Manhattan Study (NOMAS). Circulation (2008) 118:1419-24. doi:10.1161/CIRCULATIONAHA.108.771303
141. Kruit MC, van Buchem MA, Launer LJ, Terwindt GM, Ferrari MD. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia (2010) 30(2):129-36. doi:10.1111/j.1468-2982.2009.01904.x
142. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders (beta version). Cephalalgia (2013) 33(9):629-808. doi:10.1177/0333102413485658
143. Bousser MG, Welch KMA. Relation between migraine and stroke. Lancet Neurol (2005) 4(9):533-42. doi:10.1016/S1474-4422(05)70164-2
144. Garg P, Servoss SJ, Wu JC, Bajwa ZH, Selim MH, Dineen A, et al. Lack of association between migraine headache and patent foramen ovale: results of a case-control study. Circulation (2010) 121:1406-12. doi:10.1161/CIRCULATIONAHA.109.895110
145. Davis D, Gregson J, Willeit P, Stephan B, Al-Shahi Salman R, Brayne C. Patent foramen ovale, ischemic stroke and migraine: systematic review and stratified meta-analysis of association studies. Neuroepidemiology (2013) 40:56-67. doi:10.1159/000341924
146. Meschia J, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 45:3754-832. doi:10.1161/STR.0000000000000046
147. Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ (2009) 339:b3914. doi:10.1136/bmj.b3914
148. Kurth T, Schürks M, Logroscino G, Buring JE. Migraine frequency and risk of cardiovascular disease in women. Neurology (2009) 73(8):581-8. doi:10.1212/WNL.0b013e3181ab2c20
149. Tietjen GE, Khubchandani J. Platelet dysfunction and stroke in the female migraineur. Curr Pain Headache Rep (2009) 13(5):386-91. doi:10.1007/s11916-009-0063-4
150. Tietjen GE. Migraine and ischemic heart disease and stroke: potential mechanisms and treatment implications. Cephalalgia (2007) 27:981-7. doi:10.1111/j.1468-2982.2007.01407.x
151. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 352:1293-304. doi:10.1056/NEJMoa050613
152. Shi Q, Chen J, Pongmoragot J, Lanthier S, Saposnik G. Prevalence of Fabry disease in stroke patients-a systematic review and meta-analysis. J Stroke Cerebrovasc Dis (2014) 23(5):985-92. doi:10.1016/j.jstrokecerebrovasdis.2013.08.010
153. Desnick RJ, Sweeley CC. Fabry's disease: alpha-galactosidase A deficiency. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, editors. Peripheral Neuropathy. New York: McGraw Hill (1983). 2 p.
154. Eng CM, Desnick RJ. Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene. Hum Mutat (1994) 3:103. doi:10.1002/humu.1380030204
155. Eng CM, Ashley GA, Burgert TS, Enriquez AL, D'Souza M, Desnick RJ. Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med (1997) 3:174.
156. Topaloglu AK, Ashley GA, Tong B, Shabbeer J, Astrin KH, Eng CM, et al. Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease. Mol Med (1999) 5:806.
157. Wolters FJ, Rinkel GJ, Vergouwen MD. Clinical course and treatment of vertebrobasilar dolichoectasia: a systematic review of the literature. Neurol Res (2013) 35(2):131-7. doi:10.1179/1743132812Y.0000000149
158. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev (2005) 3:CD005454.
159. Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation (2001) 104:1506. doi:10.1161/hc3801.096352
160. Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry's disease. Arch Ophthalmol (1979) 97:671. doi:10.1001/archopht.1979.01020010327008
161. Maisey DN, Cosh JA. Basilar artery aneurysm and Anderson-Fabry disease. J Neurol Neurosurg Psychiatry (1980) 43:85. doi:10.1136/jnnp.43.1.85
162. Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann Neurol (1996) 40:8. doi:10.1002/ana.410400105
163. Garzuly F, Maródi L, Erdös M, Grubits J, Varga Z, Gelpi E, et al. Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the alpha-galactosidase A gene. Brain (2005) 128:2078. doi:10.1093/brain/awh546
164. Buechner S, Moretti M, Burlina AP, Cei G, Manara R, Ricci R, et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry (2008) 79:1249. doi:10.1136/jnnp.2008.143693
165. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet (2001) 38:769. doi:10.1136/jmg.38.11.750
166. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) (2002) 81:122. doi:10.1097/00005792-200203000-00003
167. Yam GH, Zuber C, Roth J. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. FASEB J (2005) 19:12. doi:10.1096/fj.04-2375com
168. Maizel SE, Simmons RL, Kjellstrand C, Fryd DS. Ten-year experience in renal transplantation for Fabry's disease. Transplant Proc (1981) 13:57.
169. Ojo A, Meier-Kriesche HU, Friedman G, Hanson J, Cibrik D, Leichtman A, et al. Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation (2000) 69:2337. doi:10.1097/00007890-200006150-00020
170. Shah T, Gill J, Malhotra N, Takemoto SK, Bunnapradist S. Kidney transplant outcomes in patients with Fabry disease. Transplantation (2009) 87:280. doi:10.1097/TP.0b013e318191a842
171. Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet (2015) 52(5):353-8. doi:10.1136/jmedgenet-2014-102797
172. Karttunen V, Alfthan G, Hiltunen L, Rasi V, Kervinen K, Kesäniemi YA, et al. Risk factors for cryptogenic ischaemic stroke. Eur J Neurol (2002) 9:625-32. doi:10.1046/j.1468-1331.2002.00464.x
173. Parnetti L, Caso V, Santucci A, Corea F, Lanari A, Floridi A, et al. Mild hyperhomocysteinemia is a risk-factor in all etiological subtypes of stroke. Neurol Sci (2004) 25:13-7. doi:10.1007/s10072-004-0219-5
174. Ribó M, Montaner J, Monasterio J, Molina C, Arenillas J, Chaócnand P, et al. Papeldelahomocisteínaen la fase hiperaguda del ictus. Neurologia (2004) 19:10.
175. Vayá A, Ejarque I, Tembl J, Corella D, Laiz B. Hyperhomocysteinemia, obesity and cryptogenic stroke. Clin Hemorheol Microcirc (2011) 47:53-8. doi:10.3233/CH-2010-1365
176. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocyst(e)ine and ischemic stroke due to large-and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke (2000) 31:1069-75. doi:10.1161/01.STR.31.5.1069
177. Hirsch S, Poniachick J, Avendaño M, Csendes A, Burdiles P, Smok G, et al. Serum folate and homocysteine levels in obese females with non-alcoholic fatty liver. Nutrition (2005) 21:137-41. doi:10.1016/j.nut.2004.03.022
178. Karatela RA, Sainani GS. Plasma homocysteine in obese, overweight and normal weight hypertensives and normotensives. Indian Heart J (2009) 61:156-9.
179. Narin F, Atabek ME, Karakukcu M, Narin N, Kurtoglu S, Gumus H, et al. The association of plasma homocysteine levels with serum leptin and apolipoprotein B levels in childhood obesity. Ann Saudi Med (2005) 25:209-14.
180. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA (1995) 274:1049-57. doi:10.1001/jama.1995.03530130055028
181. Klatsky AL, Armstrong MA, Friedman GD, Sidney S. Alcohol drinking and risk of hemorrhagic stroke. Neuroepidemiology (2002) 21:115-22. doi:10.1159/000054808
182. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med (1998) 338:1042-50. doi:10.1056/NEJM199804093381507
183. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA (1993) 270:2693-8. doi:10.1001/jama.1993.03510220049033
184. Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention: a meta-analysis. Stroke (2010) 41:1205-12. doi:10.1161/STROKEAHA.109.573410
185. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Heart outcomes prevention evaluation (HOPE) 2 investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 354:1567-77. doi:10.1056/NEJMoa060900
186. Ballabio E, Bersano A, Bresolin N, Candelise L. Monogenic vessel diseases related to ischemic stroke: a clinical approach. J Cereb Blood Flow Metab (2007) 27(10):1649-62. doi:10.1038/sj.jcbfm.9600520
187. Hassan A, Sham PC, Markus HS. Planning genetic studies in human stroke Sample size estimates based on family history data. Neurology (2002) 58(10):1483-8. doi:10.1212/WNL.58.10.1483
188. Johnson MW, Thomley ML, Huang SS, Gass JD. Idiopathic recurrent branch retinal arterial occlusion. Natural history and laboratory evaluation. Ophthalmology (1994) 101(3):480-9. doi:10.1016/S0161-6420(94)31309-1
189. Gass JD, Tiedeman J, Thomas MA. Idiopathic recurrent branch retinal arterial occlusion. Ophthalmology (1986) 93(9):1148-57. doi:10.1016/S0161-6420(86)33600-5
190. Susac JO, Hardman JM, Selhorst JB. Microangiopathy of the brain and retina. Neurology (1979) 29:313-6. doi:10.1212/WNL.29.3.313
191. Futrell N, Millikan C. Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus. Stroke (1989) 20:583. doi:10.1161/01.STR.20.5.583
192. Mikdashi J, Handwerger B, Langenberg P, Miller M, Kittner S. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke (2007) 38:281. doi:10.1161/01.STR.0000254476.05620.14
193. Krishnan E. Stroke subtypes among young patients with systemic lupus erythematosus. Am J Med (2005) 118:1415. doi:10.1016/j.amjmed.2005.05.026
194. Mitsias P, Levine SR. Large cerebral vessel occlusive disease in systemic lupus erythematosus. Neurology (1994) 44:385. doi:10.1212/WNL.44.3_Part_1.385
195. Liang MH, Karlson E. Neurologic manifestations of lupus. 2nd ed. In: Schur PH, editor. The Clinical Management of Systemic Lupus Erythematosus. Philadelphia: Lippincott (1996).
196. Roldan CA, Gelgand EA, Qualls CR, Sibbitt WL Jr. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol (2005) 95:1441-7. doi:10.1016/j.amjcard.2005.02.010
197. Nouh A, Carbunar O, Ruland S. Neurology of rheumatologic disorders. Curr Neurol Neurosci Rep (2014) 14(7):1-13. doi:10.1007/s11910-014-0456-6
198. Clinicaltrials. (2016). Available from: https://clinicaltrials.gov/ct2/show/NCT02239120 Year of public Query
199. Population Health Research Institute. (2014-2018). Available from: http://www.phri.ca/research/stroke-cognition/navigate-esus/
200. Marder VJ, Chute DJ, Starkman S, Abolian AM, Kidwell C, Liebeskind D, et al. Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke. Stroke (2005) 37(8):2086-93. doi:10.1161/01.STR.0000230307.03438.94
201. Kim SK, Yoon W, Kim TS, Kim HS, Heo TW, Park MS. Histologic analysis of retrieved clots in acute ischemic stroke: correlation with stroke etiology and gradient-echo MRI. AJNR Am J Neuroradiol (2015) 36(9):1756-62. doi:10.3174/ajnr.A4402
202. Santamarina E, Penalba A, García-Berrocoso T, Delgado P, Quintana M, González-Alujas T, et al. Biomarker level improves the diagnosis of embolic source in ischemic stroke of unknown origin. J Neurol (2012) 259(12):2538-45. doi:10.1007/s00415-012-6532-4
203. Muuronen AT, Taina M, Hedman M, Marttila J, Kuusisto J, Onatsu J, et al. Increased visceral adipose tissue as a potential risk factor in patients with Embolic Stroke of Undetermined Source (ESUS). PLoS One (2015) 10(3):e0120598. doi:10.1371/journal.pone.0120598
204. Blasi F, Oliveira BL, Rietz TA, Rotile NJ, Naha PC, Cormode DP, et al. Multisite thrombus imaging and fibrin content estimation with a single whole-body PET scan in rats. Arterioscler Thromb Vasc Biol (2015) 35(10):2114-21. doi:10.1161/ATVBAHA.115.306055